Cabaletta Bio
CABA
54 hedge funds and large institutions have $177M invested in Cabaletta Bio in 2020 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 14 increasing their positions, 22 reducing their positions, and 5 closing their positions.
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
4% more funds holding
Funds holding: 52 → 54 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.37% less ownership
Funds ownership: 68.4% → 68.03% (-0.37%)
14% less capital inflows, than outflows
Capital inflows: $5.94M | Capital outflows: $6.94M
36% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.63M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
+$400K |
| 3 |
State Street
Boston,
Massachusetts
|
+$336K |
| 4 |
California Public Employees Retirement System
Sacramento,
California
|
+$330K |
| 5 |
Nuveen
Charlotte,
North Carolina
|
+$261K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.84M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.45M |
| 3 |
Renaissance Technologies
New York
|
-$685K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$566K |
| 5 |
Redmile Group
San Francisco,
California
|
-$452K |
CABA Hedge Fund Activity: Q3 2020 in Review
54 of the 4,972 institutional investors tracked by Wall St. Rank reported a position in Cabaletta Bio (CABA) for Q3 2020, worth a combined $177M — down 3.2% from $183M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CABA positions and 5 closed out — a net gain of 2 holders — while 14 added to existing stakes and 22 trimmed.
The largest buyer was Vanguard Group, adding an estimated $3.63M. The largest seller was Adage Capital Partners, cutting an estimated $1.84M.
- 54 institutional investors held Cabaletta Bio (CABA) as of Q3 2020, up from 52 in Q2 2020.
- Funds reported $177M of Cabaletta Bio stock for Q3 2020, down 3.2% quarter-over-quarter.
- 7 funds opened new Cabaletta Bio positions in Q3 2020 and 5 closed out, a net change of +2 holders.
- The largest Cabaletta Bio buyer in Q3 2020 was Vanguard Group, an estimated $3.63M added.
- The largest Cabaletta Bio seller in Q3 2020 was Adage Capital Partners, an estimated $1.84M sold.
Based on aggregated 13F filings for Q3 2020.